Newsfeeds - Spark Newswire

1 minute read

Analyst Ratings

Piper Sandler Maintains Overweight Rating for argenx: Here’s What You Need To Know

Today, 1:03 PM

Piper Sandler has decided to maintain its Overweight rating of argenx (NASDAQ:ARGX) and raise its price target from $415.00 to $425.00. Shares of argenx are trading up 1.84% over the last 24 hours, at $363.29 per share. A move to $425.00 would account for a 16.99% increase from the current share price.

ARGX

1 minute read

Piper Sandler Maintains Overweight on argenx, Raises Price Target to $425

By Benzinga Newsdesk

Today, 1:03 PM

Piper Sandler analyst Allison Bratzel maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $415 to $425.

ARGX

1 minute read

JP Morgan Maintains Overweight on argenx, Raises Price Target to $430

By Benzinga Newsdesk

Today, 1:03 PM

JP Morgan analyst James Gordon maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $390 to $430.

ARGX

1 minute read

Piper Sandler Maintains Overweight on argenx, Raises Price Target to $415

By Benzinga Newsdesk

Today, 1:03 PM

Piper Sandler analyst Allison Bratzel maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $375 to $415.

ARGX

1 minute read

SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space

By Vandana Singh

Today, 1:03 PM

SVB Securities initiated coverage on Argenx SE (NASDAQ:ARGX) with an Outperform rating and a $404 price target. Argenx’s Vyvgart (efgartigimod) is a…

ARGX

1 minute read

Golden Cross Appears Before argenx Investors

By Benzinga Insights

Today, 1:03 PM

If history is any guide, there may be good fortune ahead for shares of argenx (NASDAQ:ARGX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

ARGX

30 minute read

Earnings Scheduled For May 5, 2022

By Benzinga Insights

Today, 1:03 PM

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

AAOI

1 minute read

Morgan Stanley Upgrades argenx to Overweight, Announces $375 Price Target

By Benzinga Newsdesk

Today, 1:03 PM

Morgan Stanley analyst Matthew Harrison upgrades argenx (NASDAQ:ARGX) from Equal-Weight to Overweight and announces $375 price target.

ARGX

1 minute read

Piper Comments On Increased Interest To Invest In Arcturus, ‘Incrementally Positive’ On Argenx

By Vandana Singh

Today, 1:03 PM

Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-COV19 vaccine candidate as a booster.

ARCT

4 minute read

The Daily Biotech Pulse: Merck’s Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout

By Shanthi Rexaline

Today, 1:03 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ADMP